What is the clinical evidence from this study?

Study design: Letter. Population: Severe obesity and subclinical atherosclerosis. Intervention: small LDL-P/medium HDL-P ratio.

February 28, 2026Open Access

Response to the letter to the Editor: Comment on “A Potential Ratio for Detecting Subclinical Atherosclerosis: Insight into Advanced NMR Lipid Profiles in Severe Obesity”

Key Result

The small LDL-P/medium HDL-P ratio serves as an exploratory, hypothesis-generating biomarker for detecting subclinical atherosclerosis in severe obesity that requires validation in larger cohorts.

Structured PICO

Population

Individuals with severe obesity (SO)

Intervention

Bariatric surgery (BS)

Outcome

Subclinical atherosclerosis (ultrasound-detected atheromatous plaque)surrogate

This editorial response clarifies that the small LDL-P/medium HDL-P ratio is an exploratory biomarker for subclinical atherosclerosis in severe obesity that requires validation in larger, adequately powered cohorts.

Limitations

Limited sample size
Exploratory study design lacking comprehensive performance metrics
Does not establish causal mechanisms
Requires external validation across diverse populations

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Carmona-Maurici et al. (Wed,) conducted a letter in Severe obesity and subclinical atherosclerosis. small LDL-P/medium HDL-P ratio was evaluated. The small LDL-P/medium HDL-P ratio serves as an exploratory, hypothesis-generating biomarker for detecting subclinical atherosclerosis in severe obesity that requires validation in larger cohorts.

synapsesocial.com/papers/6a025a419cddff7633412ab2 https://doi.org/https://doi.org/10.1007/s12265-026-10746-y